Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults.

25 Feb 2014

Onset Dermatologics launches 75mg strength of MINOCIN pellet-filled capsules to treat bacterial infections

Onset Dermatologics, a leader in developing and commercializing prescription products for improving skin health, today announced the launch of a 75mg strength of MINOCIN (minocycline hydrochloride) Pellet-Filled Capsules.

25 Feb 2014

Longer looks: Doctor training for ADHD, Obamacare and epilepsy, clues in a drop of blood

Jerry, 9 years old, dissolved into his Game Boy while his father described his attentional difficulties to the family pediatrician.

21 Feb 2014

Anaphylaxis Campaign provides updated information on Idiopathic anaphylaxis

Most people have heard of severe allergies, or anaphylaxis, to food, insect stings, drugs and other common substances, but sometimes no cause at all can be found for a person’s reaction – a condition called Idiopathic anaphylaxis.

21 Feb 2014

XenoPort reports net loss of $19.1 million for fourth quarter 2013

XenoPort, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million.

20 Feb 2014

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

CSL Behring today announced it has enrolled the first patient in COMPACT, an international phase III study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor oncentrate in patients with frequent hereditary angioedema attacks (NCT01912456).

20 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib should be given as a first-line treatment for Asian patients with advanced, epidermal growth factor receptor mutation-positive, non-small-cell lung cancer, researchers recommend.

17 Feb 2014

Discovery opens door for more targeted treatments for cancer patients

Cancer patients could one day experience fewer side effects from chemotherapy following a discovery that opens the door for more targeted treatments.

16 Feb 2014

Indoor exposure to radon gas may cause of lung cancer

Pointing to startling statistics on lung cancer risks, child health and other experts in Canada are ramping up calls for families nationwide to test their homes for radon gas contamination.

14 Feb 2014

Hospi receives FDA clearance for Macy Catheter

Hospi Corporation, a privately-held medical device company focused on nurse invented products that optimize patient care, today announced receipt of 510(k) clearance from the U.S. Food and Drug Administration for its first product, the Macy Catheter. The Macy Catheter is the only device designed and approved solely for ongoing rectal delivery of medications and liquids.

13 Feb 2014

FDA grants full approval of SYNRIBO for injection

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has granted full approval of SYNRIBO (omacetaxine mepesuccinate) for injection. This oncology portfolio product received an accelerated approval in October, 2012 with additional clinical trial data required to fulfill post marketing requirements set forth by the FDA.

13 Feb 2014

Researchers offer new options for men whose prostate cancer has spread to bones

Dartmouth-Hitchcock Norris Cotton Cancer Center has treated three men with a recently FDA-approved treatment, which offers new options for men whose prostate cancer has spread to their bones.

13 Feb 2014

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Jazz Pharmaceuticals plc today announced U.S. commercial availability of Versacloz (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder.

11 Feb 2014

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Mallinckrodt plc, a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt plc will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals, Inc. for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price (VWAP) of $10.62 per share for Cadence Pharmaceuticals, Inc.

11 Feb 2014

Viewpoints: The debate at AOL about a baby's medical costs; Gov. Jindal says economy's verdict on health law is not good

Late last week, Tim Armstrong, the chief executive officer of AOL, landed himself in a media firestorm when he held a town hall with employees to explain why he was paring their retirement benefits. After initially blaming Obamacare for driving up the company's health care costs, he pointed the finger at an unlikely target: babies. Specifically, my baby. ... ... She weighed 1 pound, 9 ounces. ... I take issue with how he reduced my daughter to a "distressed baby" who cost the company too much money. How he blamed the saving of her life for his decision to scale back employee benefits. How he exposed the most searing experience of our lives, one that my husband and I still struggle to discuss with anyone but each other, for no other purpose than an absurd justification for corporate cost-cutting (Deanna Fei, 2/9)

11 Feb 2014

KKH doctors develop novel DIVA System for blood pressure management

New trial results1 have shown that the world's first Double Intravenous Vasopressor Automated (DIVA) System affords superior control of maternal blood pressure in women undergoing caesarean section under spinal anaesthesia, when compared with manually-administered medication to manage reduced blood pressure (vasopressor).

10 Feb 2014

Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt today announced the commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knees.

10 Feb 2014

Sarepta Therapeutics reports positive safety results from AVI-7288 Phase I study

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced positive safety results from a Phase I multiple ascending dose study of AVI-7288 in healthy volunteers.

10 Feb 2014

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.

5 Feb 2014

Nausea News and Research

Further Reading

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Onset Dermatologics launches 75mg strength of MINOCIN pellet-filled capsules to treat bacterial infections

Longer looks: Doctor training for ADHD, Obamacare and epilepsy, clues in a drop of blood

Anaphylaxis Campaign provides updated information on Idiopathic anaphylaxis

XenoPort reports net loss of $19.1 million for fourth quarter 2013

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Discovery opens door for more targeted treatments for cancer patients

Indoor exposure to radon gas may cause of lung cancer

Hospi receives FDA clearance for Macy Catheter

FDA grants full approval of SYNRIBO for injection

Researchers offer new options for men whose prostate cancer has spread to bones

Jazz Pharmaceuticals' Versacloz now commercially available in the U.S. for schizophrenia

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Viewpoints: The debate at AOL about a baby's medical costs; Gov. Jindal says economy's verdict on health law is not good

KKH doctors develop novel DIVA System for blood pressure management

Mallinckrodt announces commercial launch of PENNSAID

Sarepta Therapeutics reports positive safety results from AVI-7288 Phase I study

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News